News
Bayer: The CHUM Was Ranked First in the World After Using the FAST TRACK Evaluation Service for the First Time
Bayer: The CHUM Was Ranked First in the World After Using the FAST TRACK Evaluation Service for the First Time The Bayer pharmaceutical company used the FAST TRACK Evaluation Service for the first time to accelerate the authorization of its PAnTHA advanced prostate cancer trial at the Centre hospitalier de l’Université de Montréal (CHUM) in 10.4 weeks, with site
A New Brand Identity for the FAST TRACK Evaluation Service
Almost 2 years after its inauguration, the FAST TRACK Evaluation Service is unveiling a new brand identity. Officially launched by the CATALIS Network in September 2022, the FAST TRACK Evaluation Service aims to authorize clinical trials in ≤ 8 weeks. We are pleased to announce that, to date, the service has enabled the authorization of 37 clinical trials conducted by
Pharmaceutical Company Gilead Sciences Canada Joins the CATALIS Network
Pharmaceutical Company Gilead Sciences Canada Joins the CATALIS Network CATALIS is pleased to welcome the pharmaceutical company Gilead Sciences Canada Inc. to its Network of partners. Gilead joins numerous industry partners that are actively involved in the Network: Abbvie, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vertex. These partners support
4 New Patient Organizations Join the CATALIS Network
4 New Patient Organizations Join the CATALIS Network The CATALIS Network keeps growing. Bladder Cancer Canada, and the Canadian Liver Foundation, and Fighting Blindness Canada have joined 3 patient partners and more than 30 patient organizations. Together, they represent the patient’s voice and contribute to CATALIS’ mission, which is to optimize clinical research in Quebec, in order to
The CATALIS Network Draws on the Expertise of 3 Patient Partners
The CATALIS Network Draws on the Expertise of 3 Patient Partners The CATALIS Network is delighted to rely on the support of patient partners Casandra Poitras, Raymond Vles and Catherine Wilhelmy. Catherine Wilhelmy has been a member of the Patient Advisory Committee since its inception, while Casandra Poitras and Raymond Vles are already involved in the Patient Advisory Committee
BeiGene: A First Trial Authorized With a Median Time of 8.1 Weeks
BeiGene: A First Trial Authorized With a Median Time of 8.1 Weeks Thanks to CATALIS’ FAST TRACK Evaluation Service, the BeiGene pharmaceutical company accelerated the authorization for its trial on chronic lymphoid leukemia (BGB-11417-301) in 3 Quebec hospitals with a median time of 8.1 weeks. In fact, the CHU-Sherbrooke authorized the trial in 7.8 weeks and became the first site
GSK Authorized 3 First Trials With a Median Time of 8.4 Weeks and Activated the First Site Globally
GSK Authorized 3 First Trials With a Median Time of 8.4 Weeks and Activated the First Site Globally Thanks to CATALIS’ FAST TRACK Evaluation Service and its participating healthcare institutions, the GlaxoSmithKline Inc. (GSK) pharmaceutical company was able to accelerate the authorization of three clinical trials, with a record median time of 8.4 weeks. The Galaxies 202 trial, which
Launch of Clinical Trials Quebec, Powered by Catalis, in Partnership With the Quebec Government
Launch of Clinical Trials Quebec, Powered by Catalis, in Partnership With the Quebec Government Clinical trials are an essential step in the successful development of any innovative treatment that benefits our society. Yet few people understand their importance. This is why CATALIS Quebec is proud to have coordinated the development of Clinical Trials Quebec (CTQ), a brand-new information and
A New Chair and a New Member of CATALIS Quebec’s Board of Directors
A New Chair and a New Member of CATALIS Quebec’s Board of Directors Since 2017, CATALIS Quebec’s Board of Directors (BOD) has featured experts from Quebec healthcare institutions, pharmaceutical companies, and independent directors. The Board ensures the sound governance of CATALIS and of its strategic direction, in order to implement the execution of common provincial solutions that will accelerate the discovery of innovative treatments for the benefit of the province’s patients. CATALIS is pleased to announce the appointment of Me Jean Groleau as Chair of the Board of Directors
First Pfizer Pharmaceutical Company Trial Authorized With a Median of 8.2 Weeks Using the FAST TRACK Evaluation Service
First Pfizer Pharmaceutical Company Trial Authorized With a Median of 8.2 Weeks Using the FAST TRACK Evaluation Service For the first time, the Pfizer pharmaceutical company used CATALIS’ FAST TRACK Evaluation Service to authorize a complex Phase Ia/Ib oncology clinical trial, meaning a master protocol that includes several sub-studies. In this study, Pfizer is assessing the effectiveness of a